t2513

T-2513 is a potent and specific inhibitor of topoisomerase I. It acts by forming covalent bonds with the topoisomerase I-DNA complex, thereby enhancing its stability. This interaction disrupts the normal process of DNA replication and RNA synthesis, ultimately resulting in cellular apoptosis.

VX-702 is a highly specific p38α MAPK inhibitor, 14-fold higher selectivity for the p38α than p38β. VX-702 is a small molecule investigational oral anti-cytokine therapy for treatment of inflammatory diseases, specifically rheumatoid arthritis (RA).

CVT-2513 is a metabolite of Renolazine, which has anti-myocardial ischemia effect.

T-2513 hydrochloride, a selective inhibitor of topoisomerase I, covalently binds to the topoisomerase I-DNA complex, stabilizing it and inhibiting DNA replication and RNA synthesis, ultimately leading to cell death.